Two myeloid leukemia cases with rare FLT3 fusions

Haijiao Zhang, Aleksandra Paliga, Evie Hobbs, Stephen Moore, Susan Olson, Nicola Long, Kim-Hien Dao, Jeffrey Tyner

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Genetic rearrangements involving FLT3 are rare and only recently have been detected in myeloid/lymphoid neoplasms associated with eosinophilia (MLN-eos) and chronic myeloproliferative disorders. Here we report two cases with FLT3 fusions in patients demonstrating mixed features of myelodysplastic/myeloproliferative neoplasms. In the first case, FLT3 was fused with a new fusion partner MYO18A in a patient with marrow features most consistent with atypical chronic myeloid leukemia; the second case involving ETV6-FLT3 fusion was observed in a case with bone marrow features most consistent with chronic myelomonocytic leukemia. Notably, we observed that samples from both patients demonstrated FLT3 inhibitor (quizartinib and sorafenib) sensitivity in ex vivo drug screening assay.

Original languageEnglish (US)
JournalCold Spring Harbor molecular case studies
Volume4
Issue number6
DOIs
StatePublished - Dec 1 2018

Fingerprint

Myeloid Leukemia
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
Bone Marrow
Leukemia, Myelomonocytic, Chronic
Myeloproliferative Disorders
Preclinical Drug Evaluations
Eosinophilia
Neoplasms

Keywords

  • chronic myelomonocytic leukemia
  • transient myeloproliferative syndrome

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Two myeloid leukemia cases with rare FLT3 fusions. / Zhang, Haijiao; Paliga, Aleksandra; Hobbs, Evie; Moore, Stephen; Olson, Susan; Long, Nicola; Dao, Kim-Hien; Tyner, Jeffrey.

In: Cold Spring Harbor molecular case studies, Vol. 4, No. 6, 01.12.2018.

Research output: Contribution to journalArticle

@article{1d5f9af6e46048898e6828d622262729,
title = "Two myeloid leukemia cases with rare FLT3 fusions",
abstract = "Genetic rearrangements involving FLT3 are rare and only recently have been detected in myeloid/lymphoid neoplasms associated with eosinophilia (MLN-eos) and chronic myeloproliferative disorders. Here we report two cases with FLT3 fusions in patients demonstrating mixed features of myelodysplastic/myeloproliferative neoplasms. In the first case, FLT3 was fused with a new fusion partner MYO18A in a patient with marrow features most consistent with atypical chronic myeloid leukemia; the second case involving ETV6-FLT3 fusion was observed in a case with bone marrow features most consistent with chronic myelomonocytic leukemia. Notably, we observed that samples from both patients demonstrated FLT3 inhibitor (quizartinib and sorafenib) sensitivity in ex vivo drug screening assay.",
keywords = "chronic myelomonocytic leukemia, transient myeloproliferative syndrome",
author = "Haijiao Zhang and Aleksandra Paliga and Evie Hobbs and Stephen Moore and Susan Olson and Nicola Long and Kim-Hien Dao and Jeffrey Tyner",
year = "2018",
month = "12",
day = "1",
doi = "10.1101/mcs.a003079",
language = "English (US)",
volume = "4",
journal = "Cold Spring Harbor molecular case studies",
issn = "2373-2873",
publisher = "Cold Spring Harbor Laboratory Press",
number = "6",

}

TY - JOUR

T1 - Two myeloid leukemia cases with rare FLT3 fusions

AU - Zhang, Haijiao

AU - Paliga, Aleksandra

AU - Hobbs, Evie

AU - Moore, Stephen

AU - Olson, Susan

AU - Long, Nicola

AU - Dao, Kim-Hien

AU - Tyner, Jeffrey

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Genetic rearrangements involving FLT3 are rare and only recently have been detected in myeloid/lymphoid neoplasms associated with eosinophilia (MLN-eos) and chronic myeloproliferative disorders. Here we report two cases with FLT3 fusions in patients demonstrating mixed features of myelodysplastic/myeloproliferative neoplasms. In the first case, FLT3 was fused with a new fusion partner MYO18A in a patient with marrow features most consistent with atypical chronic myeloid leukemia; the second case involving ETV6-FLT3 fusion was observed in a case with bone marrow features most consistent with chronic myelomonocytic leukemia. Notably, we observed that samples from both patients demonstrated FLT3 inhibitor (quizartinib and sorafenib) sensitivity in ex vivo drug screening assay.

AB - Genetic rearrangements involving FLT3 are rare and only recently have been detected in myeloid/lymphoid neoplasms associated with eosinophilia (MLN-eos) and chronic myeloproliferative disorders. Here we report two cases with FLT3 fusions in patients demonstrating mixed features of myelodysplastic/myeloproliferative neoplasms. In the first case, FLT3 was fused with a new fusion partner MYO18A in a patient with marrow features most consistent with atypical chronic myeloid leukemia; the second case involving ETV6-FLT3 fusion was observed in a case with bone marrow features most consistent with chronic myelomonocytic leukemia. Notably, we observed that samples from both patients demonstrated FLT3 inhibitor (quizartinib and sorafenib) sensitivity in ex vivo drug screening assay.

KW - chronic myelomonocytic leukemia

KW - transient myeloproliferative syndrome

UR - http://www.scopus.com/inward/record.url?scp=85058771561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058771561&partnerID=8YFLogxK

U2 - 10.1101/mcs.a003079

DO - 10.1101/mcs.a003079

M3 - Article

C2 - 30559310

AN - SCOPUS:85058771561

VL - 4

JO - Cold Spring Harbor molecular case studies

JF - Cold Spring Harbor molecular case studies

SN - 2373-2873

IS - 6

ER -